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2Airways hyperresponsiveness to different inhaled combination therapies 
in adolescent asthmatics.
Background: Inhaled combined therapy improves the pulmonary function in 
asthmatic patients. The effect on the airway hyperresponsiveness (AHR) and 
the efficacy of different pharmacological schedules is not well clarified on 
adolescent asthmatics.
Objective: Evaluate the responses to different combined inhaled therapies in 
adolescent asthmatics and study its impact on exercise induced AHR.
Methods: Basal lung function tests (LFT) were performed in 30 adolescents (13 
to 16 years old; 19 female) with allergic asthma. They were submitted to 
exercise challenge test (EC) followed by bronchodilator test (BD). During 4 
weeks, 15 adolescents were submitted to inhaled fluticasone/salmeterol (group 
A) and other 15 to inhaled budesonide/formoterol (group B). After this period, 
they underwent another functional evaluation as previous.
Results: Before treatment, pulmonary function was similar in both groups. After 
4 weeks of treatment, these groups showed an improvement of the basal LFT 
(p=0.001 for FEV1 in both), decrease on bronchoconstriction induced by 
exercise (NS for both) and less recovery on BD response (p=0.001 and 0.002, 
for FEV1 respectively groups A and B). Group B showed a better performance, 
with higher improvement of basal FEF 25/75 (p=0.001), reduced 
bronchoconstriction response to EC (p=0.008 for FEV1) and fewer response to 
3BD test (p<0.0001 for FEV1 and 0.024 for FEF 25/75) No adverse events were 
observed.
Conclusion: After 4 weeks of inhaled combined therapy, these patients 
improved their pulmonary function and bronchomotricity. Those under 
budesonide/formoterol showed the highest improvement. These medications 
are a safe measure in controlling the asthma in these patients.
4Introduction
The airway hyperresponsiveness (AHR) is a key feature from asthma, 
found in nearly all patients with this condition1. The intensity of AHR can greatly 
vary among patients with asthma and, also, there is a vast variability within the 
same person1. In order to understand the mechanisms of AHR, it is possible to 
consider 2 components that contribute to this response: persistent and 
variable2. The persistent component is related with structural changes in the 
airway3,4 whereas the variable component is connected with airway 
inflammation associated with allergen and occupational exposure, respiratory 
infections and treatment3,5. It is possible to establish an association between 
AHR and the severity and activity of asthma, especially when the variable 
component of AHR is analyzed3.
There are several factors that can exacerbate the AHR, such as viral 
infections, allergenic and occupational exposition, as well as exercise2. These 
factors are usually classified in those who act “directly” on specific receptors on 
the bronchial smooth muscle (direct stimuli) and stimulus that induce “indirectly” 
airway narrowing, causing the endogenous release of mediators of 
bronchoconstrition (indirect stimuli)2. The direct stimuli include agents like 
methacholine and histamine, which have a clinical and diagnostic utility2,3 , 
while the indirect stimuli include exercise and other physical stimuli and some 
chemicals, like mannitol3,6.
Exercise is an important exacerbation factor of asthma, especially in 
children7,8. The institution of adequate therapeutic measures can promote an 
5effective control of the exercise-induced symptoms9 and, being so, the 
tolerance to exercise can reflect the efficacy of asthma therapies and the 
disease control10,11.
The most important goal of asthma treatment is to achieve the disease 
control12. Children who have an uncontrolled asthma are usually under inhaled 
corticosteroids (ICS) in low-dose, so a step-up therapy should be implemented
in these patients in order to achieve asthma control, such as the ICS step-up, 
association with a long-acting β2-agonist inhaled (LABA) or association with a 
leukotriene-receptor antagonist12,13. Some studies have proved the efficacy and 
safety of these therapeutics in this specific group of patients13-16.
This study was aimed to assess the clinical and functional responses to 
two different combined inhaled therapies available in the market, studying their 
impact on exercise-induced AHR.
Methods
Patients
We selected 30 adolescent patients, aged 13 to 16 years old, with 
asthma. The inclusion criteria were moderate persistent17, controlled asthma12, 
positive skin prick tests to at least one aeroallergen and a previous lung function 
test (LFT) with positive bronchodilator test (BD).
All parents or guardians of the children gave informed consent, as well as 
the patients. This study was approved by the Institutional Review Board of the 
institution.
6Study protocol
All patients underwent a clinical observation and pletismographic test 
(MasterLab Jaeger) to determine the basal LFT. Forced expiratory volume in 
one second (FEV1), forced vital capacity (FVC), mean forced expiratory flow 
between 25% and 75% of FVC (FEF 25/75), residual volume (RV) and airway 
resistance (RAW) were evaluated. They were submitted to standardized 
treadmill exercise challenge test (EC) followed by bronchodilator test (BD). The 
procedures and the interpretation of the results were according as defined by 
ATS/ERS Task Force criteria11,18-20. The protocol used was:
1. Baseline determinations of dynamic volumes, static volumes and airways 
resistance, as the best of two measures.
2. Treadmill exercise test (Exer), while breathing ambient air (20ºC) with a 
nose clip, in order to ensure mouth breathing, and monitoring of the 
cardiac frequency. In order to achieve approximately 80% of the 
maximum predicted heart rate (220 - age in years) after a 1 minute 
warm-up at a lower work rate, the patients performed a near maximal 
constant load exercise for 6 minutes in a treadmill. At least two
acceptable FEV1 values were obtained at 1 and 5 minutes after 
cessation of exercise and the lowest FEV1 value was selected to 
calculate the fall from baseline by the following equation: % fall in FEV1 
= (pre-exercise FEV1 - lowest FEV1 post-exercise) / pre-exercise FEV1 x 
100%. The exercise test was considered positive when there was a fall in 
FEV1 ≥15%.
73. Bronchodilator test (BD), with the administration of an inhaled short 
acting b2 agonist (100 μg of albuterol) in a spacer, with the re-
assessment of the lung function 15 minutes later. A positive 
bronchodilator response was considered when there was an increase in 
FEV1 and/or FVC ≥12% of control18.
Patients then went to a randomized period of 4 weeks: 15 adolescents 
submitted to inhaled fluticasone/salmeterol (group A) and the other 15 
adolescents to inhale budesonide/formoterol (group B). All the doses were 
adjusted according to clinical, lung function, age and weight. After this period, 
all the patients underwent another functional evaluation, using the same 
protocol described above.
Primary outcome and safety evaluation
The primary outcome was the differential response to the 2 different 
inhalatory therapies, assessed by the bronchomotricity on EC and BD.
The safety was evaluated by the incidence of side effects, adverse 
events and discontinuation because of adverse events. 
8Statistical analysis
It was performed frequencies distribution, median and range according to
the groups mentioned above.
The Mann-Whitney test was used to establish the differences with
statistical significance of each respiratory factor between the two study groups. 
The Wilcoxon Signed Ranks test was applied in order to study the impact of 
physical exercise and bronchial dilation, as well as the impact of the treatment 
on each LFT parameter in each group. The statistical analysis was performed 
using SPSS 18.0® program (2007 SPSS Inc, Chicago, Ill, USA); p<0.05 was 
considered as the statistical relevance standard.
Results
Table 1 shows the demographic data and lung function test results 
according to the groups involved as well as the comparison between these 
groups. Figure 1 represents the results of the different lung function evaluations, 
before and after the treatment and according the 2 studied groups.
No patients presented asthma exacerbations during the 4 weeks period.
Before the treatment, basal LFT were similar in both groups. After the EC 
group A decreased FEV1 (p=0.004) but group B improved this LFT parameter, 
although without statistical significance. Both groups improved the FEF 25/75 
9on EC (p=0.020 for both). The BD performance was similar in the 2 groups, 
improving FEV1 (p=0.001 for both).
After 4 weeks of treatment, there was an improvement of basal FEV1 
(p=0.001 for both groups), FVC (p=0.033 and 0.177, groups A and B 
respectively), PEF (p=0.001 for both) and FEF 25/75 (p=0.001 for both groups),
with a decrease of RV (p=0.001 and 0.002, respectively groups A and B) and 
RAW (p=0.001 for both groups). The bronchial response induced by exercise 
was reduced with a less reduction on FEV1 (NS), a smaller increase of RAW 
(p=0.012) and a higher improvement of FEF 25/75 (p=0.049); it was found a
less recovery on FEV1 with the BD test (p<0.0001). However, group B showed 
a better performance, with higher improvement for basal FEF 25/75 (p=0.001), 
reduced bronchial response to EC (p=0.008 for FEV1) and a fewer response to 
the BD test (p<0.0001 for FEV1 and 0.024 for FEF 25/75).
Both medications were well tolerated in this study. No side effects were 
observed with these therapeutic measures and none of the patients has 
discontinued the treatment because of adverse events.
Discussion
In this study we have evaluated different inhaled combination therapies in 
adolescent asthmatics. All patients improved their lung function and 
bronchomotricity after 4 weeks of treatment, but those under inhaled 
budesonide/formoterol had a better response.
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We choose to study different combined inhaled therapies because this 
route of administration is the cornerstone of asthma treatment for children of all 
ages12. In addition, the combination of a different class of medication can be 
required in order to achieve the disease control13. Recently, the association of 
an inhaled LABA with an inhaled corticosteroid have been proved to be safe to 
use in children13-16. In this study we did not found any adverse event associated 
with these therapeutic measures.
The method that we used to evaluate the AHR was using the exercise as 
the provocative stimulus and then assessing the response to a bronchodilator. It 
is recognized that direct stimuli like methacholine are more sensitive in the 
diagnosis of AHR than indirect stimuli like exercise, but the last ones have a 
higher specificity and may reflect more directly the ongoing airway 
inflammation11,21. Furthermore, in children, exercise is one of the main factors of 
asthma exacerbation7 and tolerance to exercise can represent a good response 
to the therapeutics implemented, therefore to the control of the disease10.
Both groups studied were similar at the beginning, with similar 
distribution of gender, medium age and disease evolution time. The basal LFT 
before treatment did not have significant differences between the 2 groups.
The two therapeutic measures applied in this study were effective leading 
to an improvement of the several basal lung function parameters evaluated, a 
less exercise induced AHR and a less recovery on the BD test. Diverse studies 
had proved that the combination of a LABA with a ICS lead to more beneficial 
effects on lung function than increasing the dose of ICS, with increments of 
FEV1 and FEF 25/7514,16,22,23. Although the period of the study was somehow 
short, we observed significant improvements in the lung function. In a study 
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conducted by de Blic et al., they found significant enhancements of the MEF50 
after 4 weeks of treatment with salmeterol/fluticasone14. Similarly to our study, 
Fogel et al. had also obtained significant improvement of the exercise induced 
AHR after 4 weeks of inhaled salmeterol/fluticasone15. This early enhancements
may be dependent on the combination of the LABA leading to an anticipation of 
the therapeutic effects14. The reduction on the reversibility with the BD test 
observed in our study was also established by the groups mentioned before14,15.
Although the chronic use of a LABA was associated with a loss of effectiveness 
of inhaled short-acting β2-agonist as acute bronchodilator15,24 and with the
development of tolerance and increased risk of exacerbations during time25, we 
think that this decrease in reversibility is due to a pre-bronchodilator effect, 
rather than to a tolerance mechanism. Besides this, none of the patients had 
exacerbations during the study period. Even so, the long term effects of these 
therapies need to be assessed in future studies.
The protective effect of inhaled corticosteroids on exercise-induced 
asthma is considered time-dependent and is one of the clinical features which 
control is achieved later26. Despite the slight divergence related to EC observed 
before treatment in the 2 groups, there were not significant differences, in spite 
of a basal minor decrease in Group A, but the further behaviour all over the 
study was similar in both groups.
Additionally to these data, the association budesonide/formoterol was 
most likely to provide the best response in this adolescent patient group, 
however some patients presented a better response with the association 
fluticasone/salmeterol. Other groups had compared the efficacy of the different 
combined inhaled therapy plans in children. In a study conducted by Bousquet 
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et al. the therapeutic plan with budesonide/formoterol maintenance and reliever 
reduced the incidence of severe asthma exacerbations and hospitalisation/ER 
treatment with similar daily symptom control compared with sustained high-dose 
salmeterol/fluticasone plus SABA; also in this study they did not found any 
differences in measures of the lung function between the treatments27. On the 
other hand a previous study from Vogelmeier et al. found a statistically 
significant difference in post-terbutaline FEV1 in favour of patients in the 
budesonide/formoterol group, in addition to a less use of reliever therapy28. 
However none of these studies had focused the influence of these therapies in 
the exercise induced AHR. We have demonstrated that both therapeutic plans
decrease the bronchoconstriction induced by exercise, with a less recovery on 
BD, render to an airway hyperresponsiveness modulation; these facts were 
more evident in those under inhaled budesonide/formoterol.
Similarly to results reported by other studies, both medications were safe 
and well tolerated by the patients13-16,27,28.
Conclusion
In summary, in this group of adolescent asthmatics both inhaled 
therapeutic plans improved the lung function and the bronchial reactivity on the 
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Table
Group A Group B Total p
Female / Male 9 / 6 10 / 5 19 / 11
Medium age 14±3 years 14±3 years 14±3 years NS
Disease evolution time 7±8 years 6±11 years 7±11 years NS
Basal LFT
Before
FEV1 87.2012.9 88.2016.9 88.1516.9 NS
FVC 94.5012.7 94.3021.2 94.4021.2 NS
PEF 82.6017.2 82.1022.1 82.3524.2 NS
FEF 25/75 72.7030.5 74.2036.1 72.7036.1 NS
RV 121.3035.0 131.0053.0 124.7553.0 NS
RAW 162.8072.0 158.0082.0 160.4083.0 NS
EC test
Before
FEV1 83.309.7 90.1031.0 86.1031.0 0.005
FVC 94.609.1 92.9020.3 94.2020.3 NS
PEF 79.2010.7 87.3029.0 80.8029.0 0.003
FEF 25/75 77.5020.1 82.4036.4 78.9536.4 NS
RV 109.5090.0 109.5078.0 109.5098.0 NS
RAW 113.00100.1 121.00135.9 119.15135.9 NS
BD test
Before
FEV1 118.2014.3 111.4044.7 115.8544.7 0.04
FVC 101.2013.5 100.9019.9 101.2019.9 NS
PEF 110.7014.0 109.2033.0 109.7033.0 0.046
FEF 25/75 136.2030.6 126.8057.0 133.9557.0 NS
RV 88.4029.0 99.5048.0 91.4548.0 0.034
RAW 91.2051.2 89.6078.8 90.7078.8 NS
Basal LFT
After
FEV1 92.1010.6 93.8015.1 92.4517.5 NS
FVC 99.7011.2 100.2018.7 100.1518.7 NS
PEF 90.2010.0 90.0016.5 90.0517.5 NS
FEF 25/75 82.4020.4 89.0014.5 87.3522.9 0.002
RV 104.1033.0 104.0038.0 104.0543.0 NS
RAW 124.0077.0 122.0062.0 122.5089.0 NS
EC test
After
FEV1 88.3010.3 96.5021.0 91.8526.2 <0.0001
FVC 97.2010.0 101.7019.8 99.3019.8 NS
PEF 85.6013.1 94.5023.8 89.1028.9 <0.0001
FEF 25/75 90.2036.4 111.2047.7 105.2555.4 0.002
RV 102.3042.0 102.4047.0 102.3058.0 NS
RAW 110.6038.0 99.5050.0 107.3057.0 NS
BD test
After
FEV1 108.2021.1 102.3020.9 104.0523.0 NS
FVC 99.5010.0 100.7014.7 99.9016.7 NS
PEF 100.1020.3 99.7023.0 99.9023.4 NS
FEF 25/75 106.2045.6 107.0032.7 106.6047.0 NS
RV 96.2019.0 101.0039.0 98.2539.0 NS
RAW 95.9041.0 92.3087.0 93.6587.0 NS
Table 1 – Demographic and lung function data, before and after 4 weeks of 
treatment.
The results of the lung function are % of the predicted and indicated as 
median±range.
The p value corresponds to the comparison between groups A and B.
LFT – lung function test. EC – exercise challenge test. BD – bronchodilator test. 
FEV1 – forced expiratory volume in 1 second. FVC – forced vital capacity. FEF 
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25/75 – mean forced expiratory flow between 25% and 75% of FVC. RV –
residual volume. RAW – airway resistance. NS – Not significant (p>0.05).
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Figure
Figure 1 – Lung function results on the several evaluations performed (basal, 
EC and BD), before and after the treatment. Results are medians (error bars: 
95% confidence interval for median).
 - p≤0.05.  - p≤0.001. NS – not significant (p>0.05).
I – basal results before treatment. II – basal results after treatment. III – EC 
results before treatment. IV – EC results after treatment. V – BD results before 
treatment. VI – BD results after treatment.
FEV1 – forced expiratory volume in 1 second. FVC – forced vital capacity. FEF 
25/75 – mean forced expiratory flow between 25% and 75% of FVC. RV –
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